Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letolizumab in Primary ITP
NCT02273960Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2014
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label trial of letolizumab in primary immune thrombocytopenia (ITP) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of ECG Abnormalities and 1 more. Started Nov 2014; status: completed.
02
Drugs
letolizumab
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02273960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273960.